Daiichi Sankyo plans to double oncology revenue by 2030. The Japanese drugmaker aims to be a top 5 global oncology player by 2035.

While seemingly unrelated to travel, advancements in healthcare can indirectly impact your experience in Japan. A strong pharmaceutical sector contributes to the overall health and well-being of the population, potentially affecting the availability of medical services and supplies for tourists.

Daiichi Sankyo's focus on oncology drug development signifies a commitment to innovation and healthcare advancement within Japan. This investment could lead to improved medical infrastructure and access to cutting-edge treatments.

For travelers, this means potentially greater peace of mind knowing that Japan continues to invest in its healthcare system. While you hopefully won't need it, a robust healthcare sector is always a reassuring factor when traveling abroad.